CRDF News and Press, Cardiff Oncology Inc. From 11/18/21

Cardiff Oncology Announces $15 Million Equity Investment from Pfizer through its Pfizer Breakthrough Growth Initiative - Pfizer invests $15 million in Cardiff Oncology common shares - Adam Schayowitz, Ph.D., MBA, Vice President, Medicine Team Group Lead for Breast Cancer, Co...

Cardiff Oncology to Present at Upcoming Jefferies London Healthcare and Piper Sandler 33rd Annual Investor Conferences PR Newswire SAN DIEGO , Nov. 9, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new pr...

Cardiff Oncology Reports Third Quarter 2021 Results and Provides Business Updates - Announced updated clinical data from lead KRAS-mutated metastatic colorectal cancer program showing an objective response rate and median progression free survival that substantially exceed those...

CRDF's onvansertib has better data than both Amgen and Mirati in colorectal cancer. There are a few upcoming catalysts. Cash runway is decent. For further details see: Cardiff Oncology: A High Risk-Reward Opportunity In KRAS-Mutated Cancers

We are revisiting a small oncology concern called Cardiff Oncology for the first time since early this year. The company is advancing its pipeline slowly, is well funded, and has picked up some encouraging analyst support of late. A full investment analysis is provided in the para...

Cardiff Oncolog y (NASDAQ: CRDF) , a clinical-stage biotech company specializing in new cancer treatments, saw its share price rise as high as $7.18 on Monday. It closed the day at $6.74, up about 7% from its previous close. Over the past year, the stock's per-share price has ra...

Biotech and drug development news dominated Thursday's midday action. This included Biogen (NASDAQ:BIIB), which dropped to a multi-month low after its CEO warned of slower-than-expected adoption of its controversial Alzheimer’s drug. Meanwhile, smaller players in the sector received si...

Soligenix (NASDAQ:SNGX) +26% FDA Grants soligenix orphan drug designation for the treatment of T-cell lymphoma Eloxx Pharmaceuticals (NASDAQ:ELOX) +22% announces fast track designation for ELX-02 for the treatment of cystic fibrosis patients with nonsense mutations Cardiff Oncology ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! We’re starting off the day with a dive into the biggest pre-market stock movers for Thursday. Source: ventdusud / Shutterstock.com There’s a lot of reason for stocks to be moving ...

Cardiff Oncology Announces New Data from Phase 1b/2 Trial in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival PR Newswire SAN DIEGO , Sept. 8, 2021 /PRNewswire/ -- 8 of 19 (42%) patie...